SCHEMBL4735784

SCHEMBL4735784

COC(=O)C(=O)c1ccc(C(C)C)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.47
RAB9A P51151 6/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
ALDH1A1 P00352 2/20 0.46
NPC1 O15118 2/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
HPGD P15428 2/20 0.46
USP5 P45974 1/20 0.46
HTT P42858 1/20 0.44
LMNA P02545 2/20 0.43
RXRA P19793 1/20 0.42
RXRB P28702 1/20 0.42
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
KIF11 P52732 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9420297 0.83 CYP2C9 (0.57) CYP2C9RAB9ASMN1; SMN2ALDH1A1MEN1
SCHEMBL2124530 0.79 LMNA (0.48) CYP2C9RAB9ASMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL84424 0.79 CA1 (0.59) CYP2C9RAB9AL3MBTL1ALDH1A1NPC1
SCHEMBL8900283 0.79 LMNA (0.47) CYP2C9RAB9ASMN1; SMN2ALDH1A1NPC1
SCHEMBL2706993 0.79 CES2 (0.62) RAB9ASMN1; SMN2L3MBTL1ALDH1A1NPC1
SCHEMBL8165453 0.78 SMN1; SMN2 (0.43) CYP2C9RAB9ASMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL8165452 0.78 SMN1; SMN2 (0.43) CYP2C9RAB9ASMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL9420278 0.77 KIF11 (0.53) CYP2C9SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL2440560 0.77 CA1 (0.61) RAB9AL3MBTL1ALDH1A1NPC1MEN1
SCHEMBL17423644 0.77 CYP2C9 (0.62) CYP2C9RAB9ASMN1; SMN2ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070099119-A1 Photosensitive composition with low yellowing under UV-light and sunlight exposure CHEMENCE, INC. 2007-05-03 US claimed
WO-2008079519-A1 PHOTOSENSITIVE COMPOSITION WITH LOW YELLOWING UNDER UV-LIGHT AND SUNLIGHT EXPOSURE CLAST TRADING LIMITED (CN) 2008-07-03 WO disclosed
US-7309550-B2 Photosensitive composition with low yellowing under UV-light and sunlight exposure CHEMENCE, INC. (US) 2007-12-18 US disclosed
US-7220884-B2 Hydroaminomethylation of olefins DOW GLOBAL TECHNOLOGIES, INC. (US) 2007-05-22 US disclosed
US-20070099119-A1 Photosensitive composition with low yellowing under UV-light and sunlight exposure CHEMENCE, INC. 2007-05-03 US disclosed
EP-1713757-A2 HYDROAMINOMETHYLATION OF OLEFINS UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 2006-10-25 EP disclosed
US-20050215825-A1 Hydroaminomethylation of olefins UNION CARBIDE CORPORATION 2005-09-29 US disclosed
WO-2005077884-A2 HYDROAMINOMETHYLATION OF OLEFINS UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 2005-08-25 WO disclosed
US-6048852-A BACTERICIDES SMITHKLINE BEECHAM P.L.C. (GB) 2000-04-11 US disclosed
EP-0900197-A1 BETA-THIOPROPIONYL-AMINOACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 1999-03-10 EP disclosed
WO-1997030027-A1 BETA-THIOPROPIONYL-AMINOACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 1997-08-21 WO disclosed
US-4279720-A PHENYLGLYOXYLATE PHOTOINITIATOR WITH POLYALKYLPIPERIDINE STABILIZER CIBA-GEIGY CORPORATION (US) 1981-07-21 US disclosed
EP-0007059-B1 PHOTOCURABLE COMPOSITIONS CIBA-GEIGY AG (CH) 1981-04-15 EP disclosed
EP-0007059-A1 Photocurable compositions CIBA-GEIGY AG (CH) 1980-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215825-A1 Hydroaminomethylation of olefins HRH2, HRH4, HRH1 CYP2C9 438/4885RAB9A 2705/4885SMN1; SMN2 1517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.